Literature DB >> 8843547

Protection of the small intestinal clonogenic stem cells from radiation-induced damage by pretreatment with interleukin 11 also increases murine survival time.

C S Potten1.   

Abstract

The effect of administering recombinant human interleukin 11 in conjunction with cytotoxic insults to the gastrointestinal tract has been studied using the crypt microcolony assay for stem cell function and whole-animal survival time studies. The cytotoxic regimens include single doses of gamma rays; single doses of 5-fluorouracil (5-FU) and multiple doses of 5-FU spaced 6 h apart. Interleukin 11 (IL-11) (100 micrograms/kg) delivered over a period of time prior to cytotoxic exposure afforded protection to the clonogenic cells in the crypts as seen with the microcolony assay and prolonged the animal survival time following radiation exposure. Continuing this dose of IL-11 after cytotoxic exposure afforded little additional protection. Three doses of 5-FU 6 h apart generated crypt survival curves similar to those obtained after a single dose of gamma rays. IL-11 given prior to two doses of 5-FU effectively abolished the cytotoxic effect of the second dose of 5-FU; i.e., 2.5-3.0 times more crypts survived if IL-11 was administered when the higher 5-FU doses are considered. IL-11 given before a dose of 12 Gy of gamma rays prolonged the survival time of animals by three to four days. This confirms earlier studies demonstrating that protecting clonogenic cells in the crypt survival assay can result in beneficial effects on whole-animal survival times.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8843547     DOI: 10.1002/stem.140452

Source DB:  PubMed          Journal:  Stem Cells        ISSN: 1066-5099            Impact factor:   6.277


  24 in total

1.  A new class of molecular targeted radioprotectors: GSK-3beta inhibitors.

Authors:  Dinesh K Thotala; Ling Geng; Amy K Dickey; Dennis E Hallahan; Eugenia M Yazlovitskaya
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-02-01       Impact factor: 7.038

2.  PEGylated IL-11 (BBT-059): A Novel Radiation Countermeasure for Hematopoietic Acute Radiation Syndrome.

Authors:  Vidya P Kumar; Shukla Biswas; Neel K Sharma; Sasha Stone; Christine M Fam; George N Cox; Sanchita P Ghosh
Journal:  Health Phys       Date:  2018-07       Impact factor: 1.316

3.  Acute gastrointestinal syndrome in high-dose irradiated mice.

Authors:  Catherine Booth; Gregory Tudor; Julie Tudor; Barry P Katz; Thomas J MacVittie
Journal:  Health Phys       Date:  2012-10       Impact factor: 1.316

4.  Oral interleukin 11 as a countermeasure to lethal total-body irradiation in a murine model.

Authors:  Alexander F Burnett; Prabath G Biju; Huanli Lui; Martin Hauer-Jensen
Journal:  Radiat Res       Date:  2013-11-12       Impact factor: 2.841

5.  Cell kinetic studies in the murine ventral tongue epithelium: the effects of repeated exposure to keratinocyte growth factor.

Authors:  C S Potten; D Booth; N J Cragg; J A O'Shea; G L Tudor; C Booth
Journal:  Cell Prolif       Date:  2002-08       Impact factor: 6.831

Review 6.  Growth control mechanisms in normal and transformed intestinal cells.

Authors:  A W Burgess
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1998-06-29       Impact factor: 6.237

7.  Effect of interleukin-11 on ameliorating intestinal damage after methotrexate treatment of breast cancer in rats.

Authors:  Rachel J Gibson; Dorothy M K Keefe; Fiona M Thompson; Julie M Clarke; Gary J Goland; Adrian G Cummins
Journal:  Dig Dis Sci       Date:  2002-12       Impact factor: 3.199

8.  Insulin receptor substrate-1 deficiency promotes apoptosis in the putative intestinal crypt stem cell region, limits Apcmin/+ tumors, and regulates Sox9.

Authors:  Nicole M Ramocki; Heather R Wilkins; Scott T Magness; James G Simmons; Brooks P Scull; Ginny H Lee; Kirk K McNaughton; P Kay Lund
Journal:  Endocrinology       Date:  2007-10-04       Impact factor: 4.736

9.  Interleukin-11 promotes T cell polarization and prevents acute graft-versus-host disease after allogeneic bone marrow transplantation.

Authors:  G R Hill; K R Cooke; T Teshima; J M Crawford; J C Keith; Y S Brinson; D Bungard; J L Ferrara
Journal:  J Clin Invest       Date:  1998-07-01       Impact factor: 14.808

10.  Biologic targeting in the treatment of inflammatory bowel diseases.

Authors:  Matteo Bosani; Sandro Ardizzone; Gabriele Bianchi Porro
Journal:  Biologics       Date:  2009-07-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.